Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/19/2025

Role of ACE Inhibitors and Beta Blockers in Congestive Heart Failure

Introduction to ACE Inhibitors and Beta Blockers

  • The European Society of Cardiology recommends that ACE inhibitors and beta blockers should be used as first-line therapy in all patients with heart failure due to left ventricular systolic dysfunction, with ACE inhibitors initiated first, followed by beta blockers, both titrated to target doses used in clinical trials 1, 2, 3

Evidence-Based Rationale

  • Multiple randomized trials have conclusively shown that ACE inhibitors increase survival, reduce hospitalizations, and improve NYHA class and quality of life in all grades of symptomatic CHF 4
  • ACE inhibitors have been shown to delay or prevent the development of symptomatic CHF in patients with asymptomatic left ventricular systolic dysfunction 4
  • Higher doses of ACE inhibitors have been associated with greater reduction in the composite endpoint of death or hospitalization compared to lower doses (ATLAS trial) 4
  • Several major randomized controlled trials have conclusively demonstrated that beta blockers increase survival, reduce hospitalizations, and improve NYHA class and quality of life when added to standard therapy in patients with stable mild to moderate CHF 2, 3
  • The CAPRICORN study showed a reduction in mortality with carvedilol in post-myocardial infarction patients with reduced left ventricular systolic dysfunction 2, 3
  • Only three beta blockers (bisoprolol, carvedilol, and metoprolol CR/XL) have been proven to reduce mortality in heart failure 2, 3

Implementation Algorithm

  • Echocardiography, radionuclide ventriculography, or radiological left ventricular angiography should be performed to confirm the presence of left ventricular systolic dysfunction 2
  • The recommended ACE inhibitors and dosing are as follows:
ACE Inhibitor Starting dose (mg) Target dose (mg)
Captopril 6.25 thrice daily 50-100 thrice daily
Enalapril 2.5 twice daily 10-20 twice daily
Lisinopril 2.5-5.0 once daily 30-35 once daily
Ramipril 2.5 once daily 5 twice daily or 10 once daily
Trandolapril 1.0 once daily 4 once daily

1, 4

  • The recommended beta blockers and dosing are as follows:
Beta Blocker Starting dose (mg) Target dose (mg)
Bisoprolol 1.25 once daily 10 once daily
Carvedilol 3.125 twice daily 25-50 twice daily
Metoprolol CR/XL 12.5-25 once daily 200 once daily

2, 3

Special Considerations and Cautions

  • Seek specialist advice for patients with significant renal dysfunction, hyperkalaemia, or symptomatic or severe asymptomatic hypotension 1, 4
  • Seek specialist advice for patients with severe CHF, current or recent exacerbation of CHF, heart block, or heart rate < 60/min 2, 3

Managing Common Issues

  • Cough is common in CHF patients and may be due to pulmonary edema or underlying lung disease 1, 4
  • ACE inhibitor-induced cough rarely requires treatment discontinuation 1, 4
  • Temporary symptomatic deterioration may occur during initiation/up-titration of beta blockers 3
  • Patient education and close follow-up are essential during initiation and titration phases 2, 3